Welcome to our dedicated page for Bausch Health Companies news (Ticker: $BHC), a resource for investors and traders seeking the latest updates and insights on Bausch Health Companies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bausch Health Companies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bausch Health Companies's position in the market.
Salix Pharmaceuticals, a subsidiary of Bausch Health Companies Inc. (NYSE:BHC), announces Bellamy Young as the spokesperson for Xifaxan, the first FDA approved medication for reducing the risk of OHE recurrence in adults with cirrhosis. Overt Hepatic Encephalopathy is a serious complication of liver cirrhosis, affecting up to 80% of patients. Young aims to raise awareness and share her personal OHE experience to educate patients and caregivers about the management options available through the Xifaxan campaign.
Bausch Health announced first quarter 2024 results with revenues of $2.15 billion, up 11%, GAAP net loss of $64 million, and adjusted EBITDA of $665 million, up 13%. The Xifaxan appeal decision is a milestone related to Bausch + Lomb separation. R&D updates include positive data for Amiselimod and progress in other studies. Revenue growth in all segments, with reaffirmed full-year guidance.